Haematologica 2003 - Supplements

Badros A, Barlogie B, Siegel E, et al. Improved outcome of
allogeneic transplantation in high-risk multiple myeloma patients
after nonmyeloablative conditioning. J Clin Oncol 2002; 20:
1295-1303.
Kröger N, Schwerdtfeger R, Kiehl M, et al. Autologous stem cell
transplantation followed by a dose-reduced allograft induces high
complete remission rates in multiple myeloma. Blood 2002 ;
100:755-760.
Kröger N, Sayer HG, Schwerdtfeger R, et al Unrelated stem cell
transplantation in multiple myeloma after a reduced intensity
conditioning with pretransplant anti-thymocyte globulin is highly
effective with low transplantation related mortality. Blood 2002;
100: 3919-3924.
Concluding remarks on high dose therapy/stem
cell transplantation
P11.3.1
FREQUENCY AND IMPACT OF COMPLETE REMISSION
WITH INTENSIVE THERAPY FOR MULTIPLE
MYELOMA.
R. Alexanian, D. Weber, K. Delasalle, M. Wang S. Giralt,
R. Champlin
University of Texas M. D. Anderson Cancer Center, Houston,
Texas, U.S.A.
Approximately 10% of patients with multiple myeloma who
received primary therapy that included high-dose dexamethasone
achieved complete remission (CR) based on negative
immunofixation; an additional 30% of remaining patients
achieved CR with intensive therapy supported by autologous
stem cells. Most centers have reported similar findings, with
variations attributed to failure to require negative immunofixation
in defining CR, inclusion of patients with only Bence Jones
protein or “nonsecretory” disease where CR is difficult to define,
and inclusion of patients intensified after one year when there is
declining sensitivity of myeloma. Consequently, our analyses
focused on symptomatic patients 75% reduction of serum myeloma protein production
and >95% reduction of Bence Jones protein), conversion of
partial to complete remission occurred in 36%. For patients with
rapid reduction of serum myeloma protein (